Ottawa: The Health Canada on Thursday said that it has approved the Novavax Nuvaxovid’ Covid-19 dose for adults. Previously, only the two-dose primary series were approved.

The vaccine and booster are approved for people who are 18 years of age and older. Its safety and effectiveness in people younger than 18 years of age have not yet been established.

According to the clinical trials showed that beginning 1 week after the second dose, Novavax’s COVID-19 vaccine was 90% effective in protecting trial participants aged 18 and above against COVID-19

A booster dose of the Novavax Nuvaxovid® COVID-19 vaccine was shown to increase the immune response against COVID-19 in trial participants aged 18 and above.

Health Canada is to give 2 doses 21 days apart, based on evidence from clinical trials and a booster dose (5 micrograms) of the Novavax Nuvaxovid COVID-19 vaccine may be administered intramuscularly in individuals 18 years of age approximately 6 months after completing the second dose of the primary series.

The post Covid-19: Canada approves Novavax Nuvaxovid dose for adults appeared first on TV Punjab | English News Channel.